Prometrium and NSAIDs (Ibuprofen, Naproxen) Interaction

The direct answer

There is no known pharmacokinetic drug interaction between micronized progesterone (Prometrium) and NSAIDs like ibuprofen or naproxen, because they are cleared through largely separate liver enzyme pathways. The FDA-approved Prometrium label does not list NSAIDs as a contraindicated or dose-adjustment-triggering co-medication, and the FDA's own NSAID safety communications describe cardiovascular and renal risks as properties of NSAIDs generally, not as effects specific to combination with progesterone. Combining the two mainly raises the question of additive fluid retention and blood pressure effects, which matters more for women who are older, have reduced kidney function, or use NSAIDs for more than a few days at a time, than it does for occasional short-term use.

Why this question comes up for women on HRT

Women prescribed Prometrium for endometrial protection during estrogen-based hormone therapy are also a population prone to headaches, joint pain, and musculoskeletal discomfort, and ibuprofen or naproxen are typically the first medications reached for. That overlap in use is common in clinical practice, even though a formal prevalence figure specific to this exact combination was not located in the available source material and should not be asserted as a precise statistic.

Fluid retention and headache are both commonly reported adverse effects of Prometrium, according to its prescribing information. NSAIDs independently promote sodium and water retention through inhibition of renal prostaglandin synthesis. Layering these two mechanisms is the core reason this combination deserves a structured conversation rather than a reflexive "yes" or "no."

Do these drugs compete for metabolism?

No clinically established competition has been described. Micronized progesterone undergoes extensive first-pass hepatic metabolism, with CYP3A4 typically cited as a major contributing pathway. Ibuprofen and naproxen are metabolized predominantly through CYP2C9. Because the primary pathways differ, a clinically meaningful pharmacokinetic interaction (one drug raising or lowering the blood level of the other) is not expected on pharmacologic grounds. This is a mechanistic inference based on each drug's known metabolic profile rather than a finding from a dedicated interaction trial of these two specific agents; a dedicated pharmacokinetic study combining Prometrium and an NSAID was not identified in the sources reviewed for this page, and that gap should be verified against current product labeling or a pharmacist consultation before treating the "no interaction" conclusion as definitive for an individual patient.

Where the real overlap lives: pharmacodynamics

Fluid retention and blood pressure

Progesterone has some affinity for the mineralocorticoid receptor, though far weaker than aldosterone, and can contribute to mild sodium and water retention in some patients. NSAIDs reduce renal prostaglandin E2 and prostacyclin synthesis, which independently promotes sodium reabsorption and can reduce glomerular filtration. Both mechanisms push toward fluid retention through different routes, so their effects are plausibly additive even though no dedicated study of the combination was located. NSAIDs as a class are well documented to raise blood pressure modestly and increase edema risk compared to no NSAID use; the magnitude varies across trials and populations, and citing one precise number for a general reader would overstate certainty. A woman with borderline or treated hypertension is the person most likely to notice a clinically relevant shift.

Gastrointestinal irritation

Prometrium is taken orally and can cause nausea, bloating, or diarrhea in some users, per its label. NSAIDs independently damage gastric mucosa by suppressing protective prostaglandins. Combining the two may plausibly increase the frequency of mild GI symptoms, though no published data specific to this drug pair (as opposed to NSAIDs generally) were identified showing an increased rate of ulceration from this specific combination. Standard NSAID gastroprotection practice (lowest dose, shortest duration, proton pump inhibitor if other GI risk factors are present) applies regardless of concurrent progesterone use.

Thromboembolic risk: an additive population risk, not a drug-drug synergy

Combined estrogen-progestin hormone therapy is established in trial evidence to raise venous thromboembolism (VTE) risk compared to no hormone therapy; the magnitude has been reported in large randomized data such as the Women's Health Initiative, though this page will not restate that specific hazard ratio without a verified current citation. NSAIDs have also been associated with a smaller, dose-related increase in VTE risk in observational data. These are two independent risk factors acting on the same outcome, not a documented drug-drug interaction that amplifies each other mechanistically. For a woman who already carries elevated baseline clotting risk from HRT, adding a second, independent risk factor is a reasonable clinical concern even without proof of true pharmacologic synergy, and that distinction matters: additive population risk is not the same claim as a verified interaction.

What is established, what is plausible, and what remains unverified

Evidence-status assessment: Prometrium plus NSAIDs

A simple way to think about individual risk

The clinically useful question is not "can these two drugs be combined" but "how much cumulative risk does this specific patient carry before adding an NSAID." Lower risk generally describes a younger woman with normal blood pressure and kidney function using an NSAID for a few days or less. Higher risk generally describes an older woman, someone with reduced kidney function, uncontrolled blood pressure, a prior GI bleed, or anyone using an NSAID for more than a week or alongside an anticoagulant or antiplatelet medication. This is a general framework for a conversation with a prescriber, not an individualized dosing instruction.

For higher-risk patients, or anyone uncertain where they fall, acetaminophen is commonly used as an alternative that does not share the fluid-retention or GI mechanisms of NSAIDs, and topical NSAID formulations (such as diclofenac gel) produce much lower systemic drug levels than oral NSAIDs and may be a reasonable substitute for localized pain. These are general alternatives to discuss with a prescriber or pharmacist, not a recommendation tailored to any individual's kidney function, cardiovascular history, or other medications.

Monitoring conversation guide

For NSAID use expected to last more than a few days while on Prometrium, a reasonable monitoring conversation with a prescriber or pharmacist covers:

• Baseline blood pressure, and a recheck within a few weeks if NSAID use continues
• Whether kidney function has been checked recently, particularly for women over 60 or those taking an ACE inhibitor, ARB, or diuretic
• Any history of GI bleeding, ulcer disease, or concurrent aspirin or anticoagulant use
• New symptoms: ankle swelling, rapid weight gain, dark or tarry stools, new upper abdominal pain, or a meaningful rise in home blood pressure readings
• How many days the NSAID has actually been used, since risk in the literature on NSAIDs generally rises with duration, not just dose

When to seek urgent care

Sudden leg swelling with pain or warmth, chest pain, shortness of breath, vomiting blood, or black/tarry stools are not expected effects of routine concurrent Prometrium and NSAID use and warrant urgent medical evaluation rather than a routine follow-up call.

What this page does not establish

This page does not provide an individualized dosing recommendation, does not confirm the exact magnitude of any additive risk between these two drugs, and does not substitute for a review of current product labeling or a conversation with the prescriber who manages a patient's hormone therapy. Several numeric claims that circulate in consumer-facing interaction summaries for this drug pair (specific percentages, hazard ratios, or trial sample sizes) could not be traced to a verifiable, on-topic primary source during this review and have been deliberately omitted or qualified rather than repeated.